ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
Six public and private companies developing new treatment options for patients with sickle cell disease, including
Conference attendees will hear from leaders in the sickle cell disease medical and advocacy communities, including:
Lanetta B. Jordan, MD, MPH, MSPH, Associate Professor at the University of Miami Miller School of Medicineand Chief Medical Officer of the Sickle Cell Disease Association of America, Inc.(SCDAA) Kim Smith-Whitley, MD, Medical Director of the Sickle Cell Clinical Program, Clinical Director of the Division of Hematology, and Attending Physician at The Children's Hospital of Philadelphia Denis Soulieres, MD, MSc, FRCPC Director of the Molecular Biology and Hematology Laboratory, Oncology & Hematology at the University of Montreal Mary M. Hulihan, MPH, Centers for Disease Control(CDC), Division of Blood Disordersof the National Center on Birth Defects and Developmental Disabilities
Question & answer sessions will be moderated by the following healthcare analysts:
Michael Higgins, Life Sciences Analyst, Brinson Patrick Securities Corporation Michael King, Managing Director and Senior Biotechnology Analyst, Rodman & Renshaw, LLC Christian Glennie, Healthcare Analyst, Edison Investment Research, Ltd.
"We are excited to present at the
More information can be found on the conference web site at http://www.scdconference.com/ or on the advertising flyer for the event at www.scdconference.com/wp-content/uploads/2012/07/SCDTC_InformationPage.pdf.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the timing of the Phase 3 study of ANX-188 and the potential for the conference to lead to increased investment in and development of new therapies for patients with sickle cell disease. Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and those indicated from the forward-looking statements are risks and uncertainties inherent in ADVENTRX's business, including, but not limited to: the potential for delays in the commencement of planned clinical studies, including as a result of difficulties or delays in completing manufacturing process development activities and manufacturing clinical trial material or difficulties or delays in obtaining regulatory agreement on clinical study design or meeting applicable regulatory requirements for clinical trial material; the risk of suspension or termination of a clinical study including due to lack of adequate funding; the risk that planned clinical studies are not successful and, even if they are successful, that the
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.
ADVENTRX Pharmaceuticals, Ioana C. Hone (firstname.lastname@example.org), +1-858-552-0866, ext. 303